Drug Approval | February 27, 2025
Briefs: Emcure and Relonchem
USFDA inspection at Emcure Pharmaceuticals API facility
USFDA inspection at Emcure Pharmaceuticals API facility
Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA
Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
Guaifenesin extended-release tablets help to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive
The inspection was conducted at its Goa, Vema manufacturing facility
Plans to double its manufacturing footprint to bolster the growth
Access Healthcare for Medical Products (Access Healthcare) provides pharmaceutical companies with innovative marketing and sales solutions in the MENA (Middle East & North Africa) region
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs
The product will be marketed under store brand labels and is comparable to the brand Zyrtec
Subscribe To Our Newsletter & Stay Updated
